Treatment with dupilumab leads to sustained improvements in

Chronic obstructive pulmonary disease patients with type 2 inflammation saw rapid and sustained improvements in their disease after treatment with the monoclonal antibody dupilumab, according to a yearlong, Phase 3 clinical trial reported in the New England Journal of Medicine.

Related Keywords

Germany , Washington , United States , American , Lily Ramsey , Surya Bhatt , Klaus Rabe , University Of Kiel , American Thoracic Society , Marnixe Heersink School Of Medicine , International Conference , World Health Organization , New England Journal , Birmingham Department , Medicine Division , Critical Care Medicine , Lungen Clinic ,